Garcia VC, Mansfield C, Leach C, Pierce A, Smith JC, Afonso M. Patient and caregiver preferences for hemophilia treatments: a discrete-choice experiment. Haemophilia. 2024 Mar;30(2):375-87. doi: 10.1111/hae.14928
Andrews S, Mansfield C, O'Neill C, Peay H. Meaningful treatment outcomes for Sanfilippo syndrome: using a combination of focus groups and best-worst scaling to elicit and explore parents' priorities. Poster presented at the 2019 25th Annual Qualitative Health Research Conference; October 2019. Vancouver, Canada. [abstract] Int J Qual Methods. 2020 Mar 30; 19:2. doi: 10.1177/1609406920909934
Earnshaw SR, Graham CN, McDade CL, Spears JB, Kessler CM. Factor VIII alloantibody inhibitors: cost analysis of immune tolerance induction vs. prophylaxis and on-demand with bypass treatment. Haemophilia. 2015 May;21(3):310-9. doi: 10.1111/hae.12621
Kruse-Jarres R, Gilsenan AW, Spears J, Kaye JA. Prospective, observational study of plasma-derived factor VIII/von Willebrand factor in immune tolerance induction: the PRISM registry. Haemophilia. 2015 Mar;21(2):e122-4. doi: 10.1111/hae.12590
DiBenedetti DB, Coles TM, Sharma T, Pericleous L, Kulkarni R. Assessing patients' and caregivers' perspectives on stability of factor VIII products for haemophilia A: a web-based study in the United States and Canada. Haemophilia. 2014 Jul;20(4):e296-303. doi: 10.1111/hae.12459
Macdougall JE, Johnston JM, Lavins BJ, Nelson LM, Williams VS, Carson RT, Shiff SJ, Shi K, Kurtz CB, Baird MJ, Currie MG, Lembo AJ. An evaluation of the FDA Responder Endpoint for IBS-C clinical trials: analysis of data from linaclotide Phase 3 clinical trials. Neurogastroenterol Motil. 2013 Jun;25(6):481-6. doi: 10.1111/nmo.12089
Nelson LM, Williams VSL, Fehnel SE, Tourkodimitris S, Baird MJ, Carson RT, Johnston JM. Psychometric evaluation of patient-reported outcome measures for assessing chronic constipation symptom severity and change: results from phase 2b and phase 3 trials of linaclotide. Presented at the Joint International Neurogastroenterology and Motility Meeting; September 2012. [abstract] Neurogastroenterol Motil. 2012 Sep 6; 24(Suppl. s2):180.
Spiegel BMR, Locke G, Kurtz CM, Williams VSL, Nelson LM, Carson RT, Currie MG, Schneier HA, Johnston JM. Clinically meaningful change benchmarks for IBS-C symptoms developed using data from two phase 3 trials of linaclotide. Presented at the Joint International Neurogastroenterology and Motility Meeting; September 2012. Bologna, Italy. [abstract] Neurogastroenterol Motil. 2012 Sep; 24(s2):35.
Nelson LM, Williams VSL, Carson RT, Baird MJ, Fehnel SE, Johnston JM. Factor analyses of patient-reported outcome measures in Irritable Bowel Syndrome with Constipation (IBSC): results from two randomized, double-blind, placebo-controlled phase 3 trials of linaclotide. Poster presented at the Joint International Neurogastroenterology and Motility Meeting; September 2012. Bologna, Italy. [abstract] Neurogastroenterol Motil. 2012 Sep 1; 24(Suppl. 2):106. doi: 10.1111/j.1365-2982.2012.01997.x
Carson RT, Nelson LM, Williams VSL, Fehnel SE, Tourkodimitris S, Baird MJ, Johnston JM. Psychometric evaluation of patient-reported outcome measures for assessing IBS-C symptom severity and change: results from two randomized, double-blind, placebo-controlled phase 3 trials of linaclotide. Poster presented at the Joint International Neurogastroenterology and Motility Meeting; September 2012. [abstract] Neurogastroenterol Motil. 2012 Sep 1; 24(Suppl. 2):179.
Brown TM, Pashos CL, Joshi AV, Lee WC. The perspective of patients with haemophilia with inhibitors and their care givers: preferences for treatment characteristics. Haemophilia. 2011 May 1;17(3):476-82.
Brown TM, Lee WC, Joshi AV, Pashos CL. Health-related quality of life and productivity impact in haemophilia patients with inhibitors. Haemophilia. 2009 Jul 1;15(4):911-7.
Mangel AW, Fehnel SE. Design of treatment trials in irritable bowel syndrome: opioid agonists and atypical benzodiazepine antagonists. Neurogastroenterol Motil. 2008 Oct 1;20(10):1086-93.
Lee WC, Joshi AV, Woolford S, Sumner M, Brown TM, Hadker N, Pashos CL. Physicians' preferences towards coagulation factor concentrates in the treatment of haemophilia with inhibitors: a discrete choice experiment. Haemophilia. 2008 May 1;3(14):454-65.